Chicago Capital LLC Decreases Stake in Dynavax Technologies Corporation (NASDAQ:DVAX)

Chicago Capital LLC lowered its stake in shares of Dynavax Technologies Corporation (NASDAQ:DVAX - Free Report) by 0.7% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 5,344,570 shares of the biopharmaceutical company's stock after selling 36,810 shares during the period. Dynavax Technologies makes up 2.0% of Chicago Capital LLC's investment portfolio, making the stock its 16th biggest holding. Chicago Capital LLC owned about 4.31% of Dynavax Technologies worth $69,319,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds also recently made changes to their positions in the stock. Russell Investments Group Ltd. raised its holdings in shares of Dynavax Technologies by 96.5% in the 4th quarter. Russell Investments Group Ltd. now owns 2,381 shares of the biopharmaceutical company's stock worth $30,000 after acquiring an additional 1,169 shares during the last quarter. Smartleaf Asset Management LLC lifted its holdings in shares of Dynavax Technologies by 463.3% in the fourth quarter. Smartleaf Asset Management LLC now owns 2,473 shares of the biopharmaceutical company's stock valued at $32,000 after purchasing an additional 2,034 shares in the last quarter. GF Fund Management CO. LTD. bought a new position in shares of Dynavax Technologies in the fourth quarter valued at approximately $35,000. C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors purchased a new stake in Dynavax Technologies in the 4th quarter valued at $71,000. Finally, GAMMA Investing LLC lifted its stake in Dynavax Technologies by 88.4% during the 1st quarter. GAMMA Investing LLC now owns 7,729 shares of the biopharmaceutical company's stock valued at $100,000 after acquiring an additional 3,627 shares in the last quarter. Institutional investors own 96.96% of the company's stock.

Dynavax Technologies Stock Performance

Shares of NASDAQ DVAX traded down $0.31 during mid-day trading on Friday, hitting $9.99. The company had a trading volume of 5,233,680 shares, compared to its average volume of 2,215,873. The stock's 50-day moving average price is $10.32 and its 200-day moving average price is $12.09. The company has a market capitalization of $1.20 billion, a price-to-earnings ratio of -19.21 and a beta of 1.06. The company has a current ratio of 11.93, a quick ratio of 10.84 and a debt-to-equity ratio of 0.49. Dynavax Technologies Corporation has a 1 year low of $9.22 and a 1 year high of $14.63.

Dynavax Technologies (NASDAQ:DVAX - Get Free Report) last announced its quarterly earnings results on Tuesday, May 6th. The biopharmaceutical company reported ($0.11) EPS for the quarter, missing the consensus estimate of $0.03 by ($0.14). The firm had revenue of $68.16 million during the quarter, compared to the consensus estimate of $70.01 million. Dynavax Technologies had a negative net margin of 20.39% and a positive return on equity of 3.59%. On average, sell-side analysts forecast that Dynavax Technologies Corporation will post 0.32 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on DVAX. HC Wainwright reiterated a "buy" rating and issued a $31.00 target price on shares of Dynavax Technologies in a research note on Friday, February 21st. William Blair reissued an "outperform" rating on shares of Dynavax Technologies in a research report on Friday, February 21st. JMP Securities dropped their price target on Dynavax Technologies from $33.00 to $31.00 and set a "market outperform" rating on the stock in a report on Wednesday, May 7th. The Goldman Sachs Group reduced their price objective on Dynavax Technologies from $12.00 to $10.00 and set a "sell" rating for the company in a research note on Thursday, April 17th. Finally, Wall Street Zen lowered shares of Dynavax Technologies from a "buy" rating to a "hold" rating in a research report on Tuesday, May 6th. One analyst has rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of "Hold" and an average price target of $24.00.

Dynavax Technologies Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.